Angiogenesis inhibition: Drugs in clinical trials

Onkologie

Volumn 22, Issue 4, 1999, Pages 282-290

  Drevs, J ^b   Droll, A ^b   Mross, K ^a   Unger, C ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

Angiogenesis inhibition; Clinical study, phase I, II and III

Indexed keywords

4 [4,4 (CHLOROPHENYL)PHENYL] 4 OXO (PHENYLTHIOMETHYL)BUTANOIC ACID; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; CGS 27023A; CM 101; COMBRETASTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; ISOTRETINOIN; MARIMASTAT; PRINOMASTAT; PTK 787A; SEMAXANIB; SQUALAMINE; TAMOXIFEN; TECOGALAN; THALIDOMIDE; UNCLASSIFIED DRUG; ZK 22254;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; DRUG RESEARCH; HUMAN; MALIGNANT NEOPLASTIC DISEASE; REVIEW;

EID: 0032822950     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026961     Document Type: Review

References (71)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. New Engl J Med 1971;285:1182-1186.
2. Folkman J: Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1995;1:27-31.
3. Colville-Nash PR, Scott DL: Angiogenesis and rheumatoid arthritis: Pathogenic and therapeutic implications. Ann Rheum Dis 1992;51:919-925.
4. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 1986;46: 467-473.
5. Manne D: Tumor Angiogenesis: The pivotal role of vascular endothelial growth factor (VEGF). World J Urol 1996;14:166-174.
6. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung Carcinoma. Cell 1994;79:315-328.
7. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-407.
8. Ingber D, Fujita T, Kishimoto S, Sudo K: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990;348:555.
9. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J: Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 1991;174:1070-1076.
10. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormoneindependent human breast and prostate carcinoma cell lines. Cancer Res 1993;53:5233-5236.
11. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K: Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in Vitro and in vivo. Cancer Res 1993;53: 2566-2570.
12. Tanaka T, Konno H, Matsuda I, Nakamura S, Baba S: Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 1995;55:836-839.
13. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470. AGM-1470). Cancer Res 1993;53:4262-4267.
14. Bhargava P, Marshall J, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong V, Cato A, Hawkins M: A Phase-I-trial of TNP-470 in patients with advanced cancer. Proc Angiogenesis Antagonists Conference 1997, p 100.
15. Dezube J, Von Roenn JH, Holden-Wiltse J: Fuma gillin analog (TNP-470) in the treatment of Kaposi's sarcoma - a phase-I AIDS clinical trial group study. Proc Natl AIDS Malignancy Conference 1997, A35.
16. Masiero L, Figg WD, Kohn E: New anti-angiogene sis agents: Review of the clinical experience with carboxyamido-triazole, thalidomide. TNP-470 and interleukin-12. Angiogenesis 1997;1:23-35.
17. Kudelka AP, Verschraegen CF, Loyer E: Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 1998;338:991-992.
18. Levy T, Kudelka A, Verschraegen CF, Edwards CL, Freeman RS, Kaplan A, Kieback D, Steger M, Mante R, Gutterman J, Piamsomboon S, Termrungruanglert W, Kavanagh JJ: A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Proc AACR 1996;37:A1140.
19. Satoh H, Ishikawa H, Fujimoto M, Fujiwara M, Yamashita YT, Yazawa T, Ohtsuka M, Hasegawa S, Kamma H: Combined effects of TNF-470 and taxol in human non-small cell lung cancer cell lines Amicancer Res 1998;18:1027-1030.
20. Lenz W: Thalidomide and congenital abnormalities. Lancet 1962;i:45-46.
21. Jacobson JM, Greenspan JS, Spritzler J: Thalidomide for the treatment of oral aphthous ulcers in patients with human immundeficiency virus infection. N Engl J Med 1997;336:1487-1493.
22. Vogelsang GB, Farmer ER, Hess AD: Thalidomide for the treatment of chronic graft-versus host disease. N Engl J Med 1992;326:1055-1058.
23. D'Amato R, Loughnan M, Flynn E, Folkman J: Thalidomide is an inhibitor in angiogenesis. Proc Natl Acad Sci 1994;91:4082-4085.
24. Dixon SC, Bauer KS, Zalles A, Lush RM, Figg WD: Thalidomide effects on angiogenesis and PSA expression. Proc Am Ass Cancer Res 1997;38:428a.
25. Figg WD, Bergan R, Brawley O: Randomized Phase II study of thalidomide in androgen independent prostate cancer. Proc Am Soc Clin Oncol 1997;16:333a.
26. Fine HA, Loeffler JS, Kyritsis A: A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high grade gliomas. Proc Am Soc Clin Oncol 1997;16:385a.
27. Hellerqvist CG, Rojas J, Green RS, Sell S, Sundell H, Stahlman MT: Studies on group B ß-hemolytic Streptococcus. Isolation and partial characterization of an extracellular toxin. Pediatr Res 1981;15: 892-898.
28. Hellerqvist CG, Thurman GB, Page DL, Wang YF, Russel BA, Montgomery CA, Sundell HW: Anti-tumor effects of GBS toxin: a polysaccharide exotoxin from group B ß-hemolytic Streptococcus. Cancer Res Clin Oncol 1993;120:63-70.
29. Thurman GB, Russel BA, York GE, Wang YF, Page DL, Sundell HW, Hellerqvist CG: Effects of GBS toxin on long-term survival of mice bearing transplanted Madison lung tumors. Cancer Res Clin Oncol 1994;120:479-484.
30. DeVore RF, Hellerqvist CG, Wakefield GB, Wamil BD, Thurman GB, Minton PA, Sundell HW, Yan HP, Carter CE, Wang YF, York GE, Zhang MH, Johnson DH: Phase I study of the antineovascularization drug CM101. Clin Cancer Res 1997;3: 365-372.
31. Kohn EC, Felder CC, Jacobs W, Holmes KA, Day A, Freer R, Liotta LA: Structure function analysis of signal and growth inhibition by carboxyamidotriazole, CAI. Cancer Res 1994;54:935-942.
32. Felder CC, Ma AL, Liotta LA, Kohn EC: The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther 1991;257:967-971.
33. Kohn EC, Sandeen MA, Liotta A: In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate and inositol phosphates. Cancer Res 1992;52:3208-3212.
34. Kohn EC, Reed E, Sarosy E, Christian M, Link CJ, Cole KA, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 1996;56:569-573.
35. Kohn EC, Figg WD, Sarosy GA: Phase-I-trial of micronized formulation CAI in patients with refractory solid tumors: Pharmacokinetics, clinical outcome and comparison of formulations. J Clin Oncol 1997;15:1985-1993.
36. Figg WD, Cole KA, Reed E, Steinberg SM, Piscitelli SC, Davis PA, Soltis MJ, Jacob J, Boudoulas S, Goldspiel B, Sarosy G, Liotta LA, Kohn EC: Pharmacokinetics of orally administered carboxyamido-triazole (CAI), an inhibitor of calcium-mediated signal-transduction. Clin Cancer Res 1995;1:797-803.
37. Matrisan LM: Metalloproteinases and their inhibitors in matrix remodelling. Trends Gent 1990;6: 121-125.
38. Brown PD, Boxidge RE, Anderson E, Howell A: Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 1993; 11:183-189.
39. Brown PD, Bloxridge RE, Stuart NSA, Gatter KC, Carmichael J: Association between expression of activated 72-kDa gelatinase and tumour spread in non-small cell lung carcinoma. J Natl Cancer Inst 1993;85:574-578.
40. Yoshimoto M, Itoh F, Yamamoto H, Hinoda Y, Imai K, Yachi A: Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancer. Int J Cancer 1993;54:614-618.
41. Fiedler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-188.
42. Ray JM, Stetler-Stevenson WG: Matrix metalloproteinases and malignant disease: Recent developments. Exp Opin Invest Drugs 1996;5:323-335.
43. Davies B, Brown PD, East N, Crimmin MJ; Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993;53:2087-2091.
44. Porter JR, Millican TA, Morphy JR: Recent developments in matrix metalloproteinase inhibitors. Exp Opin Ther Patents 1995;5:1287-1296.
45. Wojtowicz-Praga S, Low J, Dickson R: Phase I study of Batimastat (BB-94), a novel matrix metalloproteinase inhibitor in patients with advanced cancer. Invest New Drugs 1996;14:193-202.
46. Boasberg P, Harbaugh B, Roth B: Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1996;15:258a.
47. Rosemurgy A, Harris J, Langleben A: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol 1996;15:207a.
48. Wojtowicz-Praga S, Torri J, Johnson M, Stehen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Avanzato T, Hawkins MJ: Phase-I-trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Cin Oncol 1998;16:2150-2156.
49. Santos O, McDermott CD, Daniels RG, Appelt K: Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin Exp Metastasis 1997;15: 499-508.
50. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 1993;4:197-250.
51. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marmé D: Reversion of deregulated expression of vascular endothelial growth factor in human renal cell carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996;56:2299-2301.
52. Ferrara N, Davis-Smyth T: The Biology of vascular endothelial growth factor. Endocrine Reviews 1997; 18:4-25.
53. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
54. Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Müller NPH, Risau W, Ullrich A: High affinity VEGF binding and development expression suggests FLK-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-846.
55. Barleon B, Siemeister G, Martiny-Baron G, Weindel K, Herzo C, Marmé D: Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 1997; 57:5421-5425.
56. Plowman GD, Ullrich LK, Shawver LK: Receptor tyrosine kinases as targets for drug intervention. Drug News Persp 1994;7:334-339.
57. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Schawver LK: FLK-1 as a target for tumor growth inhibition. Cancer Res 1996;56:3540-3545.
58. Schawver LK, Lipson KE, Fong TAT, Plowman GD, Strawn LM: Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Disc Today 1997; 2:50-63.
59. Wood J, Buchdunger E, Cozens R, Hofman F, Mestan J, Mett H, Roesel J, Schnell C, Stover D, Woods-Cook K, Wenger F, O'Reilly T, Bold G, Frei J, Towbin H, Schirner M, Schneider M, Martiny-Baron G, Siemeister G, Totzke F, Drevs J, Marmé D: Pharmacological profile of a potent and orally active inhibitor of VEGF receptor kinases. Proc AACR 1997, a255.
60. Rosen LS, Kabbinavar F, Rosen P, Mulay M, Quigley S, Hannah AL: Phase-I-trial of SU5416, a novel angiogenesis inhibitor, in patients with advanced malignancies. Annals Oncol 1998;9:a290.
61. Borgström P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis, and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibodies. Novel concepts og angiostatic therapy from intravital video-microscopy. Cancer Res 1996;56:4032-4039.
62. Kim KJ, Li B, Winer L, Armanini M, Gillet N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362: 841-844.
63. Steurer M: Einfluß von Isotretionin, Interferon Alfa und Tamoxifen auf die Proliferation und VEGF-Expression humaner Mammakarzinomzellen in vitro Inaugural-Diss, Med Fakultät der Albert Ludwigs-Universität Freiburg 1996.
64. Mross K, Hauns B, Häring B, Stephan P, Gastl G, Unger C: Phase II trial with retinoic acid, interferon alpha and tamoxifen (RITA) in metastatic breast cancer patients. J Cancer Res Clin Oncol 1998; 124:123.
65. Nakayama Y, Iwahana M, Sakamolo N, Tanaka NG, Osada Y: Inhibitory effects of a bacteria-derived sulfated polysaccharide against basic fibroblast growth factor-induced endothelial growth and chemotaxis. J Cell Physiol 1993;154:1-6.
66. Nakamura S, Sakurada S, Salahuddin SZ, Osada Y, Tanaka NG, Sakamoto N, Sekiguchi M, Gallo RC: Inhibition of development of Kaposi's sarcomarelated lesions by a bacterial cell wall complex. Science 1992;255:1437-1440.
67. Eckhardt SG, Burris HA, Eckhardt JR, Weiss G, Rinaldi D, Barrington R, Smith L, Fields S, Kuhn J, Smith S, Smetzer L, Marcus S, Masuo K, Sobel R, von Hoff DD: Phase I assessment of the novel angiogenesis inhibitor DS4152 (tecogalan sodium). Proc Am Soc Clin Oncol 1994;13:55.
68. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D: Isolation and structure of the strong cell growth and tubulin inhibitor combrestatin A-4. Experientia 1989;45:209-211.
69. Chaplin DJ, Pettit GR, Parkins CS, Hill SA: Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 1996;74:86-88.
70. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combrestatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:247-253.
71. Sills AK Jr, Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Cannon FH, Kinney WA, Chao TL, Donowitz M, Laterra J, Zasloff M, Brem H: Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 1998;58:2784-2792.